|
|
Volumn 59, Issue 5, 2000, Pages 1043-1055
|
|
Clinical potential of matrix metalloprotease inhibitors in cancer therapy
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
4 DEDIMETHYLAMINOSANCYCLINE;
A 177430;
BATIMASTAT;
BLEOMYCIN;
CARBOPLATIN;
CGS 27023A;
CIPEMASTAT;
COLLAGENASE;
COLLAGENASE INHIBITOR;
CYCLOPHOSPHAMIDE;
DOCETAXEL;
DOXORUBICIN;
FLUOROURACIL;
FOLINIC ACID;
GELATINASE;
GEMCITABINE;
MARIMASTAT;
MATRIX METALLOPROTEINASE;
MATRIX METALLOPROTEINASE INHIBITOR;
MITOXANTRONE;
PACLITAXEL;
PREDNISONE;
PRINOMASTAT;
PROSTATE SPECIFIC ANTIGEN;
REBIMASTAT;
RO 323555;
STROMELYSIN;
TANOMASTAT;
TETRACYCLINE;
UNCLASSIFIED DRUG;
ANGIOGENESIS;
APOPTOSIS;
BONE MARROW DEPRESSION;
CANCER;
CANCER GROWTH;
CLINICAL TRIAL;
DOSE RESPONSE;
DRUG BIOAVAILABILITY;
DRUG INHIBITION;
DRUG POTENTIATION;
DRUG WITHDRAWAL;
EDITORIAL;
ENZYME INHIBITION;
HUMAN;
JOINT STIFFNESS;
MINIMUM INHIBITORY CONCENTRATION;
NONHUMAN;
OSTEOARTHRITIS;
OVARY CANCER;
PROTEIN EXPRESSION;
RASH;
TENDINITIS;
|
|
EID: 0034036315
PISSN: 00126667
EISSN: None
Source Type: Journal
DOI: 10.2165/00003495-200059050-00002 Document Type: Editorial |
|
Times cited : (100)
|
|
References (61)
|
